Meeting
2015 ASCO Annual Meeting
Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT).
Authors
Chakra Pani Chaulagain
Cleveland Clinic Florida, Weston, FL
Chakra Pani Chaulagain , Xun Ma , Parul Doshi , Sandy Wai Kuan Wong , Andreas Kirschmer Klein , Kellie A. Sprague , Ping Zhou , Ray Comenzo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8587)
DOI
10.1200/jco.2015.33.15_suppl.8587
Abstract #
8587
Poster Bd #
405
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A first-in-class ex vivo combination between cytokine-induced memory like (CIML) NK cells and a CD38 targeting antibody recruiting molecule (ARM) as a novel approach to target NK cells without cellular engineering for the treatment of multiple myeloma.
First Author: Luca Rastelli
Poster
2019 ASCO Annual Meeting
Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma.
First Author: Ping Zhou
Poster
2016 ASCO Annual Meeting
Phase II trial of umbilical cord blood-derived natural killer cells for multiple myeloma.
First Author: Nina Shah
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess